These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 27506431)
21. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
23. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. Ferdinandus J; Eppard E; Gaertner FC; Kürpig S; Fimmers R; Yordanova A; Hauser S; Feldmann G; Essler M; Ahmadzadehfar H J Nucl Med; 2017 Feb; 58(2):312-319. PubMed ID: 27587707 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. Kim YJ; Kim YI Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870 [TBL] [Abstract][Full Text] [Related]
26. Preliminary results on response assessment using Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010 [TBL] [Abstract][Full Text] [Related]
27. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [ Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028 [TBL] [Abstract][Full Text] [Related]
28. [ Boegemann M; Schrader AJ; Rahbar K Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618 [TBL] [Abstract][Full Text] [Related]
30. Long-term survival outcomes of salvage [ Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775 [TBL] [Abstract][Full Text] [Related]
31. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [ Zang J; Wang G; Zhao T; Liu H; Lin X; Yang Y; Shao Z; Wang C; Chen H; Chen Y; Zhu Z; Miao W; Chen X; Zhang J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):871-882. PubMed ID: 37864592 [TBL] [Abstract][Full Text] [Related]
32. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application. Bal C; Yadav MP; Ballal S Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728 [TBL] [Abstract][Full Text] [Related]
33. Rahbar K; Bögemann M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):166-167. PubMed ID: 27699719 [No Abstract] [Full Text] [Related]
34. Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of Karimzadeh A; Soeiro P; Feuerecker B; Hecker CS; Knorr K; Heck MM; Tauber R; D'Alessandria C; Weber WA; Eiber M; Rauscher I J Nucl Med; 2023 Nov; 64(11):1765-1771. PubMed ID: 37678925 [TBL] [Abstract][Full Text] [Related]
35. Rahbar K; Essler M; Eiber M; la Fougère C; Prasad V; Fendler WP; Rassek P; Hasa E; Dittmann H; Bundschuh RA; Pabst KM; Kurtinecz M; Schmall A; Verholen F; Sartor O J Nucl Med; 2023 Dec; 64(12):1925-1931. PubMed ID: 37827838 [No Abstract] [Full Text] [Related]
36. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917 [TBL] [Abstract][Full Text] [Related]
37. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529 [TBL] [Abstract][Full Text] [Related]
38. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005 [TBL] [Abstract][Full Text] [Related]
39. The impact of repeated cycles of radioligand therapy using [ Yordanova A; Becker A; Eppard E; Kürpig S; Fisang C; Feldmann G; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1473-1479. PubMed ID: 28337529 [TBL] [Abstract][Full Text] [Related]
40. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]